For the first time, public-health authorities have multiple, licensed tools to prevent severe respiratory syncytial virus (RSV) disease in the groups that suffer the heaviest toll: very young infants and older adults. A protein-based maternal vaccine and several adult vaccines — including an mRNA product — won regulatory approval and programmatic endorsements in recent years, and the World Health Organization and Gavi have taken steps to help extend protection into lower‑income countries. The result is a rare, fast-moving shift from decades of hope into practical, global prevention.
Why RSV matters — and how these vaccines work
RSV causes millions of lower respiratory infections in children each year and is a major reason infants are hospitalized worldwide. Infants under six months are particularly vulnerable because their immune systems are immature and treatments are mainly supportive rather than curative. Vaccination strategies that protect infants fall into two broad approaches: maternal immunization (vaccinating pregnant people so antibodies pass to the fetus) and direct protection of infants with long‑acting monoclonal antibodies. Meanwhile, targeted adult vaccination aims to prevent severe RSV disease and hospitalizations among older people.
WHO noted that each year RSV causes more than 3.6 million hospitalizations and about 100,000 deaths in children under five, about half of which occur in infants younger than six months. ([who.int](https://www.who.int/vanuatu/news/detail-global/19-03-2025-who-prequalifies-first-maternal-respiratory-syncytial-virus-vaccine))
Licenses, recommendations and global access
In the United States and other markets, regulators have authorized multiple products for different uses. GSK’s Arexvy was the first RSV vaccine approved for older adults by the U.S. Food and Drug Administration (FDA) on May 3, 2023. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine?trk=article-ssr-frontend-pulse_little-text-block))
Pfizer’s Abrysvo, a prefusion‑F protein vaccine, received FDA approval both for adults and — importantly for global newborn protection — for use in pregnant individuals to prevent RSV disease in infants born to vaccinated mothers. The FDA approval for maternal use was announced on August 21, 2023. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants?ftag=MSF0951a18))
Moderna’s mRESVIA (an mRNA RSV vaccine) expanded the class of licensed RSV vaccines when the FDA approved it for older adults on May 31, 2024, adding an mRNA option to the prevention toolkit. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-roundup-may-31-2024))
Those regulatory steps were followed by program-level guidance in the United States. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) updated recommendations on June 26, 2024, advising a single dose of any FDA‑approved RSV vaccine for adults aged 75 and older and for adults 60–74 who are at increased risk of severe RSV disease. The guidance is intended to focus vaccination where the benefit is greatest. ([cdc.gov](https://cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm))
From approvals to global programs
Regulatory approval alone does not ensure global reach. Two developments have moved RSV maternal vaccination toward widespread use in low‑ and middle‑income countries. First, WHO prequalified the first maternal RSV vaccine (Abrysvo) on March 12, 2025 — a necessary step that allows UN procurement agencies and donors to buy the vaccine for global programs. WHO described the prequalification as a milestone that “will help keep infants out of hospitals, save lives and free up limited resources for other health priorities.” ([who.int](https://www.who.int/vanuatu/news/detail-global/19-03-2025-who-prequalifies-first-maternal-respiratory-syncytial-virus-vaccine))
Second, Gavi’s Board in July 2025 approved opening a funding window to establish a maternal RSV vaccine programme for eligible countries, signaling that donor financing and procurement pathways are being created to support introductions where the burden and need are highest. That decision followed WHO’s prequalification and lays the groundwork for country-level rollouts. ([gavi.org](https://www.gavi.org/news/media-room/gavi-board-focuses-health-impact-priority-guiding-principle-resource-constrained))
What the evidence shows
In clinical trials and real‑world studies, maternal vaccination and adult vaccines have shown strong protection against the most serious outcomes of RSV. The FDA’s product materials for maternal vaccination cite large randomized trials reporting substantial reductions in infant severe disease and hospitalizations in the months after birth; the agency’s approvals for adult vaccines were supported by trials demonstrating reduced RSV‑associated lower respiratory tract disease in older adults. Health authorities continue to monitor safety and rare events closely as use expands. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants?ftag=MSF0951a18))
What comes next — and why it’s good news
Taken together, these regulatory and programmatic moves represent a step change: pregnant‑person vaccination can protect infants during their most vulnerable months, and adult vaccination can lower hospitalizations and severe outcomes among older adults. The WHO prequalification and Gavi’s funding decision make it realistic that low‑ and middle‑income countries will be able to add maternal RSV vaccination to existing antenatal care platforms — a relatively simple delivery pathway that can reach many babies quickly.
Public‑health experts caution that implementation will take time — countries must assess cost, health‑system readiness and local RSV seasonality — but the tools to prevent the deadliest outcomes are finally in place. For parents, clinicians and older adults, that is a concrete reason for optimism: after decades of trial and error, vaccines that stop the worst RSV outcomes are moving from trials into clinics and into global programs. ([who.int](https://www.who.int/vanuatu/news/detail-global/19-03-2025-who-prequalifies-first-maternal-respiratory-syncytial-virus-vaccine))
Note: This article summarizes regulatory and program decisions from primary public‑health sources and government agencies. Readers who need clinical guidance should consult local public‑health authorities or a clinician.
